ThinkEquity Analyst Bets on Extraordinary Science and Clinical Data
Source: George S. Mack of The Life Sciences Report  (9/20/12)
Investing in companies devoted to orphan diseases sounds counterintuitive, but Senior Research Analyst Kimberly Lee of ThinkEquity has singled out the space as one with the potential for huge returns. In this exclusive interview with The Life Sciences Report, Lee shares her very best ideas, identifying companies that will be propelled by vigorously growing revenues and will also appeal to investors who understand the unmet needs of patients and the numerous incentives available for developing life-saving drugs. More >

Drug Giants Establish Problem-Solving Initiative
Source: Genetic Engineering and Biotechnology News  (9/19/12)
"Our mission at TransCelerate BioPharma is to work together across the global research and development community and share research and solutions that will simplify and accelerate the delivery of exciting new medicines for patients." More >

Are Stroke Drugs Better than Stents?
Source: Wall Street Journal, Thomas Burton  (9/18/12)
"Research that suggests prescription drugs are as good or better at preventing strokes than interventional procedures is prompting doctors to recommend against carotid surgery and carotid stent implants in most patients who haven't had stroke symptoms. The shift has broad implications for large medical-device makers that make carotid stents to open neck arteries." More >

'Cyborg' Tissue Blurs the Line Between Man and Machine
Source: Michael Robinson, Money Morning  (9/17/12)
"We're getting very close to the day in which we augment robots with 'smart' human tissue. We'll grow tissue in labs and equip it with onboard electronics made possible by nanotech circuits." More >

Medtronic Wants Drug Industry Partners for Alzheimer's
Source: Bloomberg, Michelle Fay Cortez  (9/17/12)
"The push into Alzheimer's would expand the scope of Medtronic technology that’s been used for two decades to treat pain and spasticity." More >

Apple's iPhone 5 Lightning Dock Could Drive Medical Devices to Bluetooth
Source: eweek, Brian Horowitz  (9/17/12)
"Medical devices that connect to the iPhone include glucometers, heart rate monitors and fitness sensors. The iPhone also can act as a Smart Ready hub to connect Smart peripherals, which collect data on patient vital signs." More >

Five Medtech Ideas to Leverage
Source: George S. Mack, The Life Sciences Report  (9/16/12)
Before spending the last decade as a sellside analyst, James Terwilliger, now with The Benchmark Company, worked at Johnson & Johnson and other medtech companies where he learned quickly that the way to a surgeon's heart is to bring shiny new technology into the office. Physicians who spend their working lives in interventional cath labs or hospital operating suites have a natural inclination to listen and learn about new ideas and see how the latest toys work. But medtech companies want to sell their mature product lines as well. "Face time with the physician is hugely important because that new product doesn't just drive the new business," says Terwillger. "It also puts the medical device sales force in the position to do a pull-through with other products." He learned all the tricks first-hand. More >

Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico
Source: George S. Mack of The Life Sciences Report  (9/13/12)
Biotech has a breeze to its back, and successful progression through the phases of drug development also help propel the industry forward. In this exclusive interview with The Life Sciences Report, George Zavoico, senior analyst and managing director with MLV & Co., describes solid milestones by which investors can tick off success in the biotech space, and suggests a number of innovative biotech companies whose success will blow profits into investors' pockets. More >

Biotech Bonanza of 2012
Source: Ray Blanco, The Daily Reckoning  (9/12/12)
"Favorable regulatory change is on the horizon in the biopharmaceutical industry, which should help improve conditions for innovators in the future. This is great for our portfolio going forward, as well as for the lives of patients." More >

This Tough Gel Could Replace Human Cartilage
Source: Michael Robinson, Era of Radical Change  (9/11/12)
"Breakthroughs like this will help us live longer and healthier lives. No doubt there will be plenty of opportunity for smart companies and their investors to become filthy rich in the process." More >

Drug Pipelines Limp Rather Than Leap
Source: Medical Marketing & Media, Noah Pines  (9/10/12)
"The drug industry's two main problems the last decade have been lagging R&D and the patent cliff, says Dr. Tim Anderson. Recent R&D wins suggest a productivity renaissance." More >

ENCODE Data Give 'New Lens' for Junk DNA
Source: Anette Breindl, BioWorld  (9/10/12)
"The findings will lead to 'a major paradigm shift in how we use the genome to understand the genetic causes of disease, which will open up new avenues for the development of diagnostics and therapies,' according to University of Washington's John Stamatoyannopoulos." More >

Three Easy Steps to a Well-Timed Sell
Source: Greg Guenthner, Penny Sleuth  (9/9/12)
"I'm willing to bet that you spend close to 90% of your time buying or waiting to buy. Yet you completely neglect the work that goes into selling your positions. Reverse your thinking—and put selling first—and you'll fix most of your problems." More >

Top Medtech Analyst Points to Post-Obamacare Opportunities
Source: George S. Mack of The Life Sciences Report  (9/6/12)
New product visibility is vital in medical device stories. Without something new to show physicians, there is no way to get through the door. Medical Devices and Outsourcing Services Analyst James Terwilliger of The Benchmark Company looks for investments that will pique the interests of cardiologists, orthopedists and long-term care facilities. In this exclusive interview with The Life Sciences Report, Terwilliger shares the names of companies poised to grow as the economy rebounds in the next two years. More >

Obesity Drug Developers Post Steady Gains
Source: Alex Philippidis, Genetic Engineering & Biotechnology News  (9/6/12)
"With the U.S. and the Western world increasingly overweight, companies that succeed at reversing obesity will, sooner rather than later, find themselves in Fat City." More >

Fact-Checkers Find Few Flaws in Clinton's Healthcare Claims
Source: The Hill, Sam Baker  (9/6/12)
"Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of 'fact' are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments." More >

Roche Vows to Keep Up Drug Hunt
Source: Reuters, Caroline Copley  (9/5/12)
"The world's biggest maker of cancer drugs said it would build on long-term growth momentum and keep up R&D spending." More >

Medtech Deals Buoyed by Cost Pressures, Device Tax
Source: Reuters, Debra Sherman and Soyoung Kim  (9/5/12)
"Medical device mergers look poised to take off in 2013 as the industry compensates for shrinking reimbursements, a new U.S. tax and executive shake-ups at its biggest companies." More >

Four Important Biotech Stocks Targeting Unmet Needs
Source: George S. Mack, The Life Sciences Report  (9/1/12)
Biotech rallies need catalysts to be sustained. Market moving events include drug approvals, such as a couple of obesity products from Vivus Inc. and Arena Pharmaceuticals Inc., as well as a product to help control serum lipids from Amarin Corp. Plc (AMRN:NASDAQ). But the major diagnostic feature of a market that might be putting it all together is merger and acquisition (M&A) activity. The theory is that if fully integrated, major drug developers want products and platforms. You can bet they've done their due diligence and that market conditions are nearly perfect. Even retail investors begin to pay attention. More >

Analyst Bets on Extraordinary Science and Clinical Data: Greg Wade
Source: George S. Mack of The Life Sciences Report  (8/30/12)
Managing Director Greg Wade of Wedbush Securities doesn't use a cookie-cutter approach to picking biotechnology stocks. He directs investors to companies with strong science, well-executed clinical studies and data that point toward future success. In this exclusive interview with The Life Sciences Report, Wade shares his favorite names and the compelling stories behind each company. More >

Resverlogix's Phase IIb Results Good for 'Bromodomain' Drugs
Source: Catherine Shaffer, BioWorld  (8/29/12)
"Resverlogix's RVX-208, designed to increase levels of high-density lipoprotein cholesterol in patients with atherosclerosis, is hitting all of its marks." More >

New Heart Drugs May Be Too Costly to Ease Pharma's Patent Pains
Source: Reuters, Ben Hirschler  (8/29/12)
"Leading cardiologists, who follow drug development closely, warn that the hurdle for pricey new heart medicines is getting ever higher as economic pressures hit health budgets worldwide." More >

Study Shows CT Scanning Technology Superior
Source: Medical Xpress  (8/29/12)
"An important noninvasive technology may improve existing care and has the potential to outperform established noninvasive technologies." More >

Filling the Drug Translation Gap
Source: Alex Philippidis, Genetic Engineering & Biotechnology News  (8/29/12)
"Patients keep waiting longer and longer for research to translate into new drugs as development costs rise. The best hope for bridging that gap—thus cutting time and money from drug development—rests with translation-focused disease foundations." More >

Gemoscan Sets Aggressive Expansion Plan
Source: BioTuesdays, Leonard Zehr  (8/28/12)
"The company is planning expansion in the U.S., Europe, Asia and India, with a growth objective of 10,000 locations by 2014." More >